Zentalis Pharmaceuticals (ZNTL) Income from Non-Controlling Interests (2019 - 2024)
Zentalis Pharmaceuticals (ZNTL) posted quarterly Income from Non-Controlling Interests of -$28000.0 for Q1 2024, up 34.88% year-over-year from -$20758.6 in Q2 2023, and down 27.27% quarter-over-quarter from -$22000.0 in Q4 2023.
Zentalis Pharmaceuticals (ZNTL) Income from Non-Controlling Interests (2019 - 2024) Analysis & Trends
Zentalis Pharmaceuticals' Income from Non-Controlling Interests history runs 6 years deep, the most recent figure standing at -$28000.0 for Q1 2024.
- In Q1 2024, Income from Non-Controlling Interests rose 34.88% year-over-year to -$28000.0; the TTM figure through Dec 2024 stood at -$28000.0 (up 75.44% YoY), while the FY2024 annual figure was -$28000.0, up 75.44% from the prior year.
- Income from Non-Controlling Interests for Q1 2024 stood at -$28000.0, down from -$22000.0 in the prior quarter.
- The five-year high for Income from Non-Controlling Interests was -$12000.0 in Q3 2023, with the low at -$6.3 million in Q3 2021.
- The 5-year median for Income from Non-Controlling Interests is -$53000.0 (2020), against an average of -$501411.8.
- The sharpest annual moves came in 2021 and 2022: Income from Non-Controlling Interests tumbled 5628.18% in 2021, then jumped 98.43% in 2022.
- Zentalis Pharmaceuticals' Income from Non-Controlling Interests stood at -$53000.0 in 2020, then jumped by 32.08% to -$36000.0 in 2021, then jumped by 63.89% to -$13000.0 in 2022, then tumbled by 69.23% to -$22000.0 in 2023, then decreased by 27.27% to -$28000.0 in 2024.
- Business Quant data shows ZNTL's Income from Non-Controlling Interests at -$28000.0 in Q1 2024, -$22000.0 in Q4 2023, and -$12000.0 in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 63.60 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Zentalis Pharmaceuticals | 255.14 Mn | 255.14 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | -28,000.00 |
| Dec 31, 2023 | -22,000.00 |
| Sep 30, 2023 | -12,000.00 |
| Jun 30, 2023 | -37,000.00 |
| Mar 31, 2023 | -43,000.00 |
| Dec 31, 2022 | -13,000.00 |
| Sep 30, 2022 | -99,000.00 |
| Jun 30, 2022 | -35,000.00 |
| Mar 31, 2022 | -160,000.00 |
| Dec 31, 2021 | -36,000.00 |
| Sep 30, 2021 | -6.30 Mn |
| Jun 30, 2021 | -488,000.00 |
| Mar 31, 2021 | -543,000.00 |
| Dec 31, 2020 | -53,000.00 |
| Sep 30, 2020 | -110,000.00 |
| Jun 30, 2020 | -435,000.00 |
| Mar 31, 2020 | -109,000.00 |
| Dec 31, 2019 | -40,000.00 |
| Sep 30, 2019 | -228,000.00 |
| Jun 30, 2019 | -127,000.00 |